News for Orchard Therapeutics plc (ORTX)

Orchard Therapeutics (ORTX) has launched the most expensive drug of 2024. Lenmeldy is a gene therapy priced at $4.25 million. This sets a new standar

**media[445453]**

Third quarter 2024 total revenues increased by 12% to US$74.8 million, compared to the third quarter 2023, driven by continued strong RUCONEST® and Joenja®...

Savara appoints Braden Parker as Chief Commercial Officer

Westford, USA, Sept. 12, 2024 (GLOBE NEWSWIRE) -- SkyQuest projects that the Global Gene Therapy Market will reach a value of USD 38.34 Billion by 2031,...

Second quarter 2024 total revenues increased by 35% to US$74.1 million, compared to the second quarter 2023, driven by strong RUCONEST® and Joenja® revenue...

First quarter 2024 revenues increased by 31% to US$55.6 million, compared to the first quarter 2023, driven by the U.S. commercial launch of Joenja® and...

Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List

TIME Reveals the Inaugural TIME100 Health List of the World's Most Influential People in Health

Zolgensma came to the market five years ago with a price tag of $2.1 million. What happened to it?

Kyowa Kirin's gene therapy most expensive US drug with $4.3 million price tag

Prominence of Personalized Medicine Approaches as a Notable Trend in the Hemoglobinopathy Market...

Discover the ROTY Biotech Community, a platform for investors seeking valuable insights and recommendations in the ever-growing biotech industry.

Orchard Therapeutics plc (ORTX) is up over 97% in pre-market trading. Here is a list of some of the other stocks making big moves in Thursday's pre-market trading.

Orchard Therapeutics plc (ORTX) is up over 97% in pre-market trading. Here is a list of some of the other stocks making big moves in Thursday's pre-market trading.

Increase in the prevalence of chronic diseases, advances in stem cell research, and growth in investment in regenerative medicine are prominent factors...

/PRNewswire/ -- DelveInsight's Mucopolysaccharidosis Market Insights report includes a comprehensive understanding of current treatment practices,...

The United Kingdom, like the rest of the world, is facing the negative effects of the Russian invasion of Ukraine and rising inflation.

[115+ Pages Research Study] According to Polaris Market Research report, the global cancer gene therapy market size & share expected to generate revenue of...